https://www.selleckchem.com/products/secinh3.html Stroke is still the most significant problem of the modern medicine and the leading cause of mortality and morbidity. There is the great experience of neuroprotection in patients with stroke in the Russian Federation. In clinical practice it's important to follow conditions, where neuroprotection will have maximum safety and effectiveness. The clinical trials of ethylmethylhydroxypyridine succinate (mexidol) in patients with acute ischemic stroke are described in the present review. Early management (in the first 6 hours) with mexidol significantly improve recovery dynamic and stroke outcome. Therapy with mexidol increases neurological recovery, improves vital activity and quality of life of patients with stroke. Furthermore, mexidol demonstrates high safety profile. To assess the efficacy and safety of amantadine sulfate in patients with ischemic stroke. Ninety five patients with ischemic stroke were randomized within 120 hours from the onset of symptoms into two groups patients of the main group received amantadine sulfate (400 mg/day intravenously) for 4 days, followed by oral administration at 400 mg/day for 6 days; the comparison group received standard therapy according to the order of the Ministry of Health of the Russian Federation No. 928n. The observation period for the patients was 90 days. The main indicators of treatment efficacy were Glasgow Coma Scale (GCS), Modified Rankin Scale (mRS), Bartel Index (BI), National Institutes of Health Stroke Scale (NIHSS), and mortality. Any side effects were recorded to assess safety. There were no statistically significant differences between the main group and the comparison group for the main parameters. However, we observed better results in patients with mild stroke (NIHSS <13 points) and atherothrombotic pathogenetic variant of ischemic stroke. This observation should be confirmed in subsequent clinical studies. There were no statistically significant difference